Novartis’s Zykadia ASCENDs First-Line NSCLC Heights But Roche’s Alecensa Gives Chase

Novartis’s anticancer Zykadia is catching up its rival, Pfizer’s Xalkori, by showing a benefit when used first line in the Phase III ASCEND-4 study in NSCLC, but must still look over its shoulder at Roche’s Alecensa.

Sunrise in Snowy Mountains
• Source: Shutterstock

Top-line results from the Phase III ASCEND-4 study show that Novartis AG’s oral, selective inhibitor anaplastic lymphoma kinase (ALK) inhibitor Zykadia (ceritinib) has met its primary endpoint in improving progression-free survival compared with standard chemotherapy in the first-line treatment of patients with advanced anaplastic lymphoma kinase-positive (ALK+) non-small cell lung cancer (NSCLC).

The data look set to propel the product into the frontline for advanced disease where it would go up against...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Anticancer

More from Therapeutic Category